Haverford Trust Company Has Upped Anheuser (BUD) Holding By $1.49 Million; Manatuck Hill Partners Increased Cytosorbents (CTSO) Stake By $508,200

June 14, 2018 - By Adrian Mccoy

Cytosorbents Corporation (NASDAQ:CTSO) Logo

Haverford Trust Company increased Anheuser (BUD) stake by 1.69% reported in 2018Q1 SEC filing. Haverford Trust Company acquired 13,710 shares as Anheuser (BUD)’s stock declined 13.10%. The Haverford Trust Company holds 827,321 shares with $90.96M value, up from 813,611 last quarter. Anheuser now has $189.30 billion valuation. The stock decreased 0.22% or $0.22 during the last trading session, reaching $97.58. About 782,813 shares traded. Anheuser-Busch InBev SA/NV (NYSE:BUD) has declined 19.97% since June 14, 2017 and is downtrending. It has underperformed by 32.54% the S&P500. Some Historical BUD News: ; 03/05/2018 – Anheuser-Busch Will Buy Nikola’s Hydrogen-Powered Trucks; 09/05/2018 – AB InBev 1Q Revenue, Adjusted Ebitda Rose; 04/04/2018 – Magners cider maker C&C buys Conviviality wholesale arm; 25/04/2018 – AB INBEV HOPES CONGRESS INTERVENES IN ALUMINUM MIDWEST PREMIUM; 09/05/2018 – AB InBev 1Q Net Pft $1.44B; 04/04/2018 – C&C Group In Talks With Support of AB InBev; 17/04/2018 – Brewing powerhouse Anheuser-Busch unveils ambitious sustainability targets; 07/05/2018 – ANHEUSER-BUSCH INBEV TO REDEEM USD 1B NOTES DUE 2020; 25/04/2018 – Bud brewer hopeful that aluminium tariffs won’t hit U.S. allies; 14/05/2018 – Arrowstreet Adds AB InBev, Cuts Philip Morris: 13F

Manatuck Hill Partners Llc increased Cytosorbents Corp (CTSO) stake by 41.82% reported in 2018Q1 SEC filing. Manatuck Hill Partners Llc acquired 72,600 shares as Cytosorbents Corp (CTSO)’s stock rose 42.04%. The Manatuck Hill Partners Llc holds 246,200 shares with $1.74M value, up from 173,600 last quarter. Cytosorbents Corp now has $356.01M valuation. The stock increased 5.80% or $0.65 during the last trading session, reaching $11.85. About 218,540 shares traded. Cytosorbents Corporation (NASDAQ:CTSO) has risen 156.32% since June 14, 2017 and is uptrending. It has outperformed by 143.75% the S&P500. Some Historical CTSO News: ; 28/03/2018 – CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference; 08/03/2018 CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017; 14/05/2018 – CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use; 28/03/2018 – CytoSorbents at Non-Deal Roadshow Hosted By LifeSci Advisors; 20/04/2018 – DJ CytoSorbents Corporation, Inst Holders, 1Q 2018 (CTSO); 21/05/2018 – CytoSorbents Presenting at Conference May 23; 08/05/2018 – CYTOSORBENTS CORP – EXPECT SECOND QUARTER 2018 PRODUCT SALES TO EXCEED PRODUCT SALES REPORTED IN THE FIRST QUARTER OF 2018; 23/03/2018 – CytoSorbents Access Event Set By LifeSci Advisors for Mar. 28; 08/03/2018 – CYTOSORBENTS CORP CTSO.O : COWEN AND COMPANY RAISES TARGET PRICE TO $9 FROM $7; 08/03/2018 – Cytosorbents 2017 Loss/Shr 32c

Haverford Trust Company decreased Wells Fargo Co (NYSE:WFC) stake by 2.04 million shares to 263,279 valued at $13.80 million in 2018Q1. It also reduced Stryker Corp (NYSE:SYK) stake by 3,070 shares and now owns 8,042 shares. Ww Grainger Inc (NYSE:GWW) was reduced too.

Among 23 analysts covering Anheuser-Busch InBev (NYSE:BUD), 17 have Buy rating, 2 Sell and 4 Hold. Therefore 74% are positive. Anheuser-Busch InBev had 54 analyst reports since July 21, 2015 according to SRatingsIntel. As per Monday, November 14, the company rating was downgraded by HSBC. The company was maintained on Tuesday, September 8 by RBC Capital Markets. Macquarie Research initiated Anheuser-Busch InBev SA/NV (NYSE:BUD) on Friday, November 25 with “Outperform” rating. The rating was downgraded by RBC Capital Markets to “Underperform” on Wednesday, July 6. The company was reinitiated on Wednesday, October 5 by Morgan Stanley. The firm earned “Hold” rating on Friday, May 5 by Susquehanna. The rating was maintained by Goldman Sachs with “Buy” on Monday, July 10. The firm has “Buy” rating by Stifel Nicolaus given on Friday, February 26. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, April 18. The firm has “Buy” rating by HSBC given on Monday, June 4.

More notable recent Anheuser-Busch InBev SA/NV (NYSE:BUD) news were published by: Seekingalpha.com which released: “Premium water specialist Essentia in play” on June 14, 2018, also 247Wallst.com with their article: “Merrill Lynch Says Buy US Stocks Now – 4 Top Picks For The Rest Of 2018” published on June 14, 2018, Finance.Yahoo.com published: “How to Invest in Craft Beer” on June 12, 2018. More interesting news about Anheuser-Busch InBev SA/NV (NYSE:BUD) were released by: Fool.com and their article: “Price Increases, Cost Savings Drive Anheuser-Busch InBev Results” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “Why Invest In Companies That Partner With Sports Leagues?” with publication date: June 03, 2018.

Investors sentiment increased to 1 in Q1 2018. Its up 0.04, from 0.96 in 2017Q4. It improved, as 54 investors sold BUD shares while 149 reduced holdings. 57 funds opened positions while 147 raised stakes. 95.25 million shares or 1.22% more from 94.11 million shares in 2017Q4 were reported. Welch And Forbes Limited Com has 216,941 shares. Pathstone Family Office Limited Liability Corp reported 0% in Anheuser-Busch InBev SA/NV (NYSE:BUD). San Francisco Sentry Group Incorporated (Ca) owns 1,304 shares for 0.04% of their portfolio. First Financial In holds 487 shares. Bollard Grp Inc Limited Liability invested in 119 shares or 0% of the stock. Perkins Coie reported 95 shares. Valley National Advisers Inc reported 0.03% stake. Jfs Wealth Advsrs Ltd Com holds 17 shares or 0% of its portfolio. 9,590 are held by East Coast Asset Mngmt Ltd Liability Co. Whittier Company Of Nevada has invested 0.12% in Anheuser-Busch InBev SA/NV (NYSE:BUD). Neuberger Berman Grp Incorporated Limited Liability Com holds 0.01% in Anheuser-Busch InBev SA/NV (NYSE:BUD) or 80,481 shares. Exane Derivatives stated it has 48,092 shares. Emerging Sovereign Ltd Llc holds 5.24% or 210,037 shares in its portfolio. 10 has invested 0.05% in Anheuser-Busch InBev SA/NV (NYSE:BUD). Bbva Compass Comml Bank accumulated 2,323 shares.

Manatuck Hill Partners Llc decreased Acacia Resh Corp (NASDAQ:ACTG) stake by 150,400 shares to 388,100 valued at $1.36 million in 2018Q1. It also reduced Red Lion Hotels Corp (NYSE:RLH) stake by 391,252 shares and now owns 695,640 shares. Vicor Corp (NASDAQ:VICR) was reduced too.

Investors sentiment decreased to 2.36 in Q1 2018. Its down 0.53, from 2.89 in 2017Q4. It worsened, as 4 investors sold CTSO shares while 7 reduced holdings. 10 funds opened positions while 16 raised stakes. 3.72 million shares or 28.01% more from 2.91 million shares in 2017Q4 were reported. Citadel Ltd Liability Company owns 0% invested in Cytosorbents Corporation (NASDAQ:CTSO) for 11,291 shares. Millennium Mngmt Limited Com accumulated 0% or 384,330 shares. The New York-based Blackrock Incorporated has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). State Street Corporation invested in 0% or 21,579 shares. Moreover, Bluecrest Limited has 0.02% invested in Cytosorbents Corporation (NASDAQ:CTSO). Deutsche Bancorp Ag holds 77,704 shares or 0% of its portfolio. Credit Suisse Ag reported 0% in Cytosorbents Corporation (NASDAQ:CTSO). Granite Inv Partners Ltd Com reported 58,851 shares. Prelude Cap Management Limited Com reported 0% stake. Natl Bank Of America Corporation De invested in 0% or 31,463 shares. Morgan Stanley invested in 23,193 shares. Crow Point Prtnrs Limited Liability owns 10,656 shares. Retail Bank Of New York Mellon Corporation holds 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO) for 29,506 shares. 19,500 are owned by Pnc Services Gru. Thompson Davis & holds 0.02% or 1,250 shares in its portfolio.

Since January 8, 2018, it had 0 insider buys, and 10 selling transactions for $819,400 activity. BLOCH KATHLEEN P. sold 32,400 shares worth $236,400. Shares for $43,614 were sold by Capponi Vincent.

More news for Cytosorbents Corporation (NASDAQ:CTSO) were recently published by: Streetinsider.com, which released: “Form 8-K Cytosorbents Corp For: Jun 12” on June 14, 2018. Prnewswire.com‘s article titled: “CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference” and published on June 04, 2018 is yet another important article.

Among 7 analysts covering CytoSorbents (NASDAQ:CTSO), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents had 16 analyst reports since October 29, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group on Monday, July 17 with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Friday, March 9. As per Wednesday, July 5, the company rating was maintained by Maxim Group. Aegis Capital maintained the shares of CTSO in report on Tuesday, May 30 with “Buy” rating. Maxim Group initiated Cytosorbents Corporation (NASDAQ:CTSO) rating on Tuesday, May 24. Maxim Group has “Buy” rating and $8 target. The rating was initiated by B. Riley & Co on Friday, October 7 with “Buy”. The firm earned “Buy” rating on Wednesday, October 26 by Aegis Capital. The stock of Cytosorbents Corporation (NASDAQ:CTSO) has “Buy” rating given on Tuesday, September 26 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, January 9. The rating was maintained by Maxim Group with “Buy” on Tuesday, August 8.

Cytosorbents Corporation (NASDAQ:CTSO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: